Complete tumor encapsulation on magnetic resonance imaging: A potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma

David S. Lu, Surachate Siripongsakun, Jeong Kyong Lee, Sindy H. Wei, Phillip M. Cheng, Saman Sabounchi, Jong Seok Lee, Steven Raman, Myron J. Tong, Ronald W. Busuttil, James Sayre – 24 December 2012 – The aim of this study was to determine the prognostic value of complete tumor encapsulation as visualized on magnetic resonance imaging (MRI) in patients with a solitary large hepatocellular carcinoma (HCC) beyond the Milan criteria for liver transplantation (LT).

Chronic hepatitis C virus (HCV) disease burden and cost in the United States

Homie Razavi, Antoine C. ElKhoury, Elamin Elbasha, Chris Estes, Ken Pasini, Thierry Poynard, Ritesh Kumar – 22 December 2012 – Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. A better understanding of HCV disease progression and the associated cost can help the medical community manage HCV and develop treatment strategies in light of the emergence of several potent anti‐HCV therapies. A system dynamic model with 36 cohorts was used to provide maximum flexibility and improved forecasting.

Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus–infected and ‐uninfected men who have sex with men

Yu‐Tzu Tseng, Sui‐Yuan Chang, Wen‐Chun Liu, Hsin‐Yun Sun, Cheng‐Hsin Wu, Pei‐Ying Wu, Ching‐Lan Lu, Chien‐Ching Hung, Shan‐Chwen Chang – 19 December 2012 – The purpose of this prospective cohort study was to compare the serologic response between human immunodeficiency virus (HIV)‐infected men who have sex with men (MSM) receiving two and three doses of hepatitis A virus (HAV) vaccine and HIV‐uninfected MSM receiving two doses of HAV vaccine. Between June 2009 and December 2010, 582 MSM aged 18 to 40 years who were seronegative for HAV were enrolled in the study.

Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumor formation in serially transplanted rodents

Ina Rittelmeyer, Michael Rothe, Martijn H. Brugman, Marcus Iken, Axel Schambach, Michael P. Manns, Christopher Baum, Ute Modlich, Michael Ott – 19 December 2012 – Lentiviral (LV) vectors are promising tools for long‐term genetic correction of hereditary diseases. In hematopoietic stem cell gene therapies adverse events in patients due to vector integration‐associated genotoxicity have been observed. Only a few studies have explored the potential risks of LV gene therapy targeting the liver.

Subscribe to